Compare Neurocrine Biosciences Inc (NBIX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Schlumberger NV — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 5.1× Neurocrine Biosciences Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Schlumberger NV for 99 Days on average.
| NBIX | SLB | |
|---|---|---|
Market Cap | $14.36B | $72.69B |
Volume | 1,237,180 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $185.50 | $60.10 |
52-Week Low | $123.10 | $31.72 |
Typical Hold Time | 23 Days | 99 Days |
Enterprise Value | $14.37B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
SLB trades at $48.95, up 2.06% today, but technical indicators signal a bearish trend with key support at $48. The company reported revenue of $35.71B in 2025 with a net income margin of 8.53%, though margins have softened from prior years. Recent contract wins in Oman and Mozambique bolster long-term revenue visibility, while analyst consensus remains strongly bullish with an average price target of $64.58.
The stock presents a value opportunity given analyst optimism and strategic contract expansions, but faces headwinds from declining profit margins and bearish technical momentum. Earnings beats in recent quarters support fundamental strength, yet investors must weigh execution risks against the potential for significant upside relative to the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
